Innovative hypertension treatments: Transitioning from conventional therapies to siRNA-based solutions

IF 4.2 3区医学 Q1 PHARMACOLOGY & PHARMACY

European journal of pharmacology Pub Date : 2024-11-14 DOI:10.1016/j.ejphar.2024.177110

Reza Parvan , Joseph Pierre Aboumsallem , Wouter C. Meijers , Rudolf A. De Boer , A.H. Jan Danser

{"title":"Innovative hypertension treatments: Transitioning from conventional therapies to siRNA-based solutions","authors":"Reza Parvan , Joseph Pierre Aboumsallem , Wouter C. Meijers , Rudolf A. De Boer , A.H. Jan Danser","doi":"10.1016/j.ejphar.2024.177110","DOIUrl":null,"url":null,"abstract":"<div><div>Hypertension remains a critical global health issue, despite significant advancements in treatment, management and preventive approaches. Current antihypertensive drugs have limitations, such as low adherence, renin-angiotensin-aldosterone system reactivation, and drug resistance,. Ongoing preclinical and clinical studies for siRNA therapies show promising results, demonstrating significant blood pressure reductions and their potential as effective, durable treatments.</div><div>This narrative review explores the potential of siRNA therapies in transforming hypertension management covering the literature until May 2024 and offering a precision medicine approach. We searched various databases, including PubMed, <span><span>http://www.clinicaltrial.gov</span><svg><path></path></svg></span>, and <span><span>www.Espacenet.com</span><svg><path></path></svg></span>, using ‘hypertension’ and ‘siRNA’ as the main keywords to retrieve relevant studies.</div><div>The impact of these therapies could be profound, offering improved efficacy, reduced side effects, and enhanced patient adherence. As research continues to validate their safety and effectiveness, siRNA therapies may become integral components of hypertension management.</div></div>","PeriodicalId":12004,"journal":{"name":"European journal of pharmacology","volume":"985 ","pages":"Article 177110"},"PeriodicalIF":4.2000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0014299924008008","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Hypertension remains a critical global health issue, despite significant advancements in treatment, management and preventive approaches. Current antihypertensive drugs have limitations, such as low adherence, renin-angiotensin-aldosterone system reactivation, and drug resistance,. Ongoing preclinical and clinical studies for siRNA therapies show promising results, demonstrating significant blood pressure reductions and their potential as effective, durable treatments.

This narrative review explores the potential of siRNA therapies in transforming hypertension management covering the literature until May 2024 and offering a precision medicine approach. We searched various databases, including PubMed, http://www.clinicaltrial.gov, and www.Espacenet.com, using ‘hypertension’ and ‘siRNA’ as the main keywords to retrieve relevant studies.

The impact of these therapies could be profound, offering improved efficacy, reduced side effects, and enhanced patient adherence. As research continues to validate their safety and effectiveness, siRNA therapies may become integral components of hypertension management.

查看原文本刊更多论文

创新的高血压治疗方法：从传统疗法过渡到基于 siRNA 的解决方案。

尽管在治疗、管理和预防方法方面取得了重大进展，但高血压仍然是一个严重的全球健康问题。目前的抗高血压药物有其局限性，如依从性低、肾素-血管紧张素-醛固酮系统再激活和耐药性等。正在进行的 siRNA 疗法的临床前和临床研究显示出良好的效果，血压明显降低，并有可能成为有效、持久的治疗方法。这篇叙述性综述探讨了 siRNA 疗法在改变高血压管理方面的潜力，涵盖了 2024 年 5 月之前的文献，并提供了一种精准医疗方法。我们使用 "高血压 "和 "siRNA "作为主要关键词检索了多个数据库，包括 PubMed、www.clinicaltrial.gov 和 www.Espacenet.com，以检索相关研究。这些疗法能提高疗效、减少副作用并增强患者的依从性，其影响可能是深远的。随着研究不断验证其安全性和有效性，siRNA疗法可能会成为高血压治疗不可或缺的组成部分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European journal of pharmacology 医学-药学

CiteScore

9.00

自引率

0.00%

发文量

572

审稿时长

34 days

期刊介绍： The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems. The scope includes: Behavioural pharmacology Neuropharmacology and analgesia Cardiovascular pharmacology Pulmonary, gastrointestinal and urogenital pharmacology Endocrine pharmacology Immunopharmacology and inflammation Molecular and cellular pharmacology Regenerative pharmacology Biologicals and biotherapeutics Translational pharmacology Nutriceutical pharmacology.